Drug intelligence / Profile preview

mezlocillin

Development stage
Discontinued
Lead developer
Bayer
Modality
Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

Mezlocillin is a broad-spectrum semisynthetic penicillin antibiotic of the ureidopenicillin subclass. It is derived from ampicillin and was developed by Bayer. Mezlocillin acts by binding to penicillin-binding proteins (PBPs) in bacterial cell walls, inhibiting the final stage of peptidoglycan synthesis and leading to cell lysis. It is active against a wide range of Gram-negative bacteria (including *Pseudomonas aeruginosa*, *Escherichia coli*, *Klebsiella* species) as well as some Gram-positive organisms. Unlike most extended-spectrum penicillins, it is primarily excreted via the liver and thus useful for biliary tract infections such as ascending cholangitis. Mezlocillin was administered intravenously or intramuscularly due to poor oral absorption and has been discontinued in the United States[1][2][5].

Brand names
MezlinBAYPEN
Other names
mezlocillin sodium
02

Targets

PBP2 (Penicillin-binding protein 2)PBP1A (Penicillin-binding protein 1A)

Beyond the preview

Go deeper on mezlocillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mezlocillin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call